SCHEMBL1339302

SCHEMBL1339302

O=C(O)Cc1nc(NC(=O)Nc2ccc(Cl)cc2C(=O)C2CCCC2)sc1S(=O)(=O)c1ncc[nH]1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
GRM4 Q14833 5/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PLA2G1B P04054 1/20 0.31
ATG4B Q9Y4P1 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
SERPINE1 P05121 1/20 0.30
F10 P00742 1/20 0.30
RORC P51449 1/20 0.30
BRAF P15056 1/20 0.30
KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342803 0.91 LMNA (0.32) MAPTHTTKMT2AGRM4RAB9A
SCHEMBL1341797 0.91 LMNA (0.35) GCKMAPTKMT2AGRM4RAB9A
SCHEMBL1342078 0.91 RORC (0.34) KDM4EMAPTHTTKMT2AGRM4
SCHEMBL1342389 0.90 MAPT (0.37) KDM4EMAPTHTTKMT2ARAB9A
SCHEMBL1341606 0.89 MAPT (0.31) MAPTKMT2ARORC
SCHEMBL1342853 0.89 GRM4 (0.32) KDM4EMAPTHTTKMT2AGRM4
SCHEMBL1342316 0.89 KDR (0.35) BRAFKDRIDH2
SCHEMBL1342926 0.89 CCNE1 (0.33) GCKRORC
SCHEMBL1342832 0.89 GRM4 (0.33) KDM4EMAPTHTTKMT2AGRM4
SCHEMBL1341157 0.88 RAB9A (0.35) KDM4EMAPTHTTKMT2AGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 GCK 1/4885KDM4E 992/4885MAPT 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.